BIOMAT Database Logo BIOMAT Database Logo

Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma. 2023

Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
Shang-Xiao Huang, MD, Peng-Hui Luo, MD, Han-Lei Wang, MD, Dun-Chang Mo, MD, and Jian-Feng Huang, MD, Radiotherapy Department, Nanning Second People's Hospital, Nanning, Guangxi, China.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069286 Bortezomib A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. LDP-341,PS 341,PS-341,Velcade,341, PS,LDP 341,LDP341,PS341
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
NICE guidance on daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma.
May 2019, The Lancet. Oncology,
Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
August 2016, The New England journal of medicine,
Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
December 2023, The New England journal of medicine,
Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
August 2020, Clinical lymphoma, myeloma & leukemia,
Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.
March 2023, Targeted oncology,
Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
Venetoclax in Combination With Bortezomib, Dexamethasone, and Daratumumab for Multiple Myeloma.
September 2018, Clinical lymphoma, myeloma & leukemia,
Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
September 2021, American journal of hematology,
Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
March 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
Paraneoplastic aortitis in a patient with relapsed multiple myeloma successfully treated with daratumumab, bortezomib and dexamethasone.
June 2021, Annals of hematology,
Shang-Xiao Huang, and Peng-Hui Luo, and Han-Lei Wang, and Dun-Chang Mo, and Jian-Feng Huang
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
February 2016, Blood,
Copied contents to your clipboard!